GATA-3 as a Marker of Hormone Response in Breast Cancer

Journal of Surgical Research

Volumn 157, Issue 2, 2009, Pages 290-295

  Fang, Sandy H ^a   Chen, Yizhen ^a   Weigel, Ronald J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

breast cancer; estrogen receptor; GATA 3; hormone response

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TAMOXIFEN; TRANSCRIPTION FACTOR GATA 3;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HORMONE RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE MICROARRAY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70450228907     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.07.015     Document Type: Review

References (59)

1. Berg J.M., Tymoczko J.L., and Stryer L. Biochemistry. 5th ed. (2002), Freeman, New York: W.H
2. Thomas M.C., and Chiang C.M. The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol 41 (2006) 105
3. Lowry J.A., and Atchley W.R. Molecular evolution of the GATA family of transcription factors: Conservation within the DNA-binding domain. J Mol Evol 50 (2000) 103
4. Patient R.K., and McGhee J.D. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev 12 (2002) 416
5. Ho I.C., and Pai S.Y. GATA-3-not just for Th2 cells anymore. Cell Mol Immunol 4 (2007) 15
6. Naylor M.J., and Ormandy C.J. Gata-3 and mammary cell fate. Breast Cancer Res 9 (2007) 302
7. Asselin-Labat M.L., Sutherland K.D., Barker H., et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9 (2007) 201
8. Kouros-Mehr H., Slorach E.M., Sternlicht M.D., et al. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127 (2006) 1041
9. Hendriks R.W., Nawijn M.C., Engel J.D., et al. Expression of the transcription factor GATA-3 is required for the development of the earliest T cell progenitors and correlates with stages of cellular proliferation in the thymus. Eur J Immunol 29 (1999) 1912
10. Ting C.N., Olson M.C., Barton K.P., et al. Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 384 (1996) 474
11. Pai S.Y., Truitt M.L., Ting C.N., et al. Critical roles for transcription factor GATA-3 in thymocyte development. Immunity 19 (2003) 863
12. Lim K.C., Lakshmanan G., Crawford S.E., et al. Gata-3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genet 25 (2000) 209
13. van Doorninck J.H., van Der Wees J., Karis A., et al. GATA-3 is involved in the development of serotonergic neurons in the caudal raphe nuclei. J Neurosci 19 (1999) RC12
14. Grote D., Souabni A., Busslinger M., et al. Pax 2/8-regulated Gata-3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development (Cambridge, England) 133 (2006) 53
15. van der Wees J., van Looij M.A., de Ruiter M.M., et al. Hearing loss following Gata-3 haploinsufficiency is caused by cochlear disorder. Neurobiol Dis 16 (2004) 169
16. Kaufman C.K., Zhou P., Pasolli H.A., et al. GATA-3: An unexpected regulator of cell lineage determination in skin. Genes Dev 17 (2003) 2108
17. Pang W.W., and Hartmann P.E. Initiation of human lactation: Secretory differentiation and secretory activation. J Mammary Gland Biol Neoplasia 12 (2007) 211
18. Lanigan F., O'Connor D., Martin F., et al. Molecular links between mammary gland development and breast cancer. Cell Mol Life Sci 64 (2007) 3159
19. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003) 8418
20. Tong Q., and Hotamisligil G.S. Developmental biology: Cell fate in the mammary gland. Nature 445 (2007) 724-726
21. Oncomine Research Platform: www.oncomine.org. Rhodes DR. Oncomine: A cancer microarray database and integrated data-mining platform. Neoplasia 2004. ed. p. 1.
22. Farmer P., Bonnefoi H., Becette V., et al. Identification of molecular apocrine breast tumors by microarray analysis. Oncogene 24 (2005) 4660
23. Richardson A.L., Wang Z.C., De Nicolo A., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9 (2006) 121
24. Hoch R.V., Thompson D.A., Baker R.J., et al. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84 (1999) 122
25. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 347 (2002) 1999
26. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236
27. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671
28. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518
29. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 (2007) 3207
30. Saal L.H., Johansson P., Holm K., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104 (2007) 7564
31. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529
32. Gruvberger S., Ringner M., Chen Y., et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61 (2001) 5979
33. Yu K., Ganesan K., Miller L.D., and Tan P. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res 12 (2006) 3288
34. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100 (2003) 10393
35. Bild A.H., Yao G., Chang J.T., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353
36. Ivshina A.V., George J., Senko O., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66 (2006) 10292
37. Ginestier C., Cervera N., Finetti P., et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12 (2006) 4533
38. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102 (2005) 13550
39. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262
40. West M., Blanchette C., Dressman H., et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98 (2001) 11462
41. Voduc D., Cheang M., and Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 17 (2008) 365
42. Jordan V.C., Wolf M.F., Mirecki D.M., et al. Hormone receptor assays: Clinical usefulness in the management of carcinoma of the breast. Crit Rev Clin Lab Sci 26 (1988) 97
43. Eeckhoute J., Keeton E.K., Lupien M., et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 67 (2007) 6477
44. Carroll J.S., Liu X.S., Brodsky A.S., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33
45. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Medicine 351 (2004) 2817
46. Parikh P., Palazzo J.P., Rose L.J., et al. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg 200 (2005) 705
47. Knight W.A., Livingston R.B., Gregory E.J., et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37 (1977) 4669
48. Knight III W.A., Osborne C.K., Yochmowitz M.G., et al. Steroid hormone receptors in the management of human breast cancer. Ann Clin Res 12 (1980) 202
49. Bertucci F., Houlgatte R., Benziane A., et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 9 (2000) 2981
50. Mehra R., Varambally S., Ding L., et al. Identification of GATA-3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65 (2005) 11259
51. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumors. Nature 406 (2000) 74
52. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
53. Jenssen T.K., Kuo W.P., Stokke T., et al. Associations between gene expressions in breast cancer and patient survival. Hum Genet 111 (2002) 411
54. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
55. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
56. Morgan Jr. L.R., Schein P.S., Woolley P.V., et al. Therapeutic use of tamoxifen in advanced breast cancer: Correlation with biochemical parameters. Cancer Treat Rep 60 (1976) 1437
57. Osborne C.K. Tamoxifen in the treatment of breast cancer. New Engl J Med 339 (1998) 1609
58. Raab S.S. The cost-effectiveness of immunohistochemistry. Arch Pathol Lab Med 124 (2000) 1185
59. Usary J., Llaca V., Karaca G., et al. Mutation of GATA3 in human breast tumors. Oncogene 23 (2004) 7669